Categories: News

SERES Showcases Industry-Leading Innovations at Auto Guangzhou, Setting the Pace for the Future

GUANGZHOU, China, Nov. 22, 2025 /PRNewswire/ — The full AITO product lineup and SERES’ latest technological achievements were showcased at the Guangzhou International Automobile Exhibition. Simultaneously, the SERES MF Platform 2.0 was grandly unveiled.

- Advertisement -

Intelligence Redefines Luxury: AITO Full Model Lineup Appears

- Advertisement -

This year’s auto show marks AITO’s largest presence ever in terms of scale and lineup. The latest products from the entire AITO series were exhibited together, with cumulative deliveries exceeding 900,000 units. Among them, the AITO M9 and AITO M8 ranked as sales champions in their respective 500,000-RMB and 400,000-RMB price segments.

- Advertisement -

AITO’s newly upgraded 1,700-square-meter booth featured technology display and luxury experience zones, vividly interpreting the brand declaration of “Intelligence Redefines Luxury.”

- Advertisement -

SERES MF Platform 2.0 Launched, Defining New Heights for Future Smart Mobility

- Advertisement -

The SERES MF Platform 2.0 was officially launched at the show. Guided by Panoramic Intelligence and built upon a foundation of intelligent safety, this platform represents a comprehensive upgrade in Smart Energy, Intelligent Chassis, EEA Architecture, and Intelligent Space. It is an AI-driven platform for smart electric vehicles.

- Advertisement -

The latest technological achievements were also displayed, including a 2.0T range extender and a 14-in-1 ultra-integrated range extension system, making their debut at a domestic auto show.

- Advertisement -

AITO User Base Surpasses 900,000, Total Assisted Driving Mileage Exceeds 4.45 Billion Kilometers

- Advertisement -

To date, AITO has earned the trust of 900,000 users. The total mileage covered by its intelligent range-extended electric vehicles has surpassed 21.4 billion kilometers, with pure electric driving accounting for 70% of this distance. The cumulative assisted driving mileage has exceeded 4.45 billion kilometers.

- Advertisement -

Furthermore, AITO has proactively provided service care 266,000 times and saved users over 440,000 hours in maintenance time through remote diagnostics, setting a new benchmark for premium service.

- Advertisement -

SERES will continue to develop high-end products for users, characterized by high safety, high quality, high reliability, high performance, and high value.

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/seres-showcases-industry-leading-innovations-at-auto-guangzhou-setting-the-pace-for-the-future-302623865.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

8 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

8 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

8 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

8 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

8 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

8 hours ago